RNAi Message Board - Msg: 24081391

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: jh2006	11/24/2007 10:49:42 PM
	of 671

I just heard Senetek's conference call. The CEO said that NONE of the 46 patients in the drug trial for their RNAi treatment for brain tumors have died. The trial is not finished yet and is taking place in Poland. One patient is alive after 2 years and had a life expectancy of less than 8 months. He is back to work! .............................................................. ...here's the press release from a year ago... Senetek Gains RNAi Technology for Treating Brain Tumors Nov 7 2006, 1:57 PM EST GEN News Highlights Senetek obtained exclusive rights to RNAi anticancer technology for brain tumors and three compounds for the treatment of skin aging from the Institute of Bioorganic Chemistry of the Polish Academy of Sciences. The anticancer technology uses RNAi to inhibit the production of tenascin-C, which when expressed seems to correlate with the level of brain tumor malignancy, explains Senetek. The technology was recently applied to patients with glioblastoma multiforme with resounding success, reports the company. It was developed by the Institute in cooperation with Department of Neurosurgery and Neurotraumatology University of Medical Sciences in Poznan, Poland. "The current options for patients with brain tumors consist of treatments such as surgery and chemotherapy and/or radiotherapy; which have an average survival time of only eight to 10 months,” notes Frank Massino, CEO and chairman of Senetek. “This new technology works not only to prolong the survival of patients suffering from brain tumors, but possibly to cure them as well."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next